Worth reading
47Recurring
Scored from 4 of 5 sectionsDirection
Mixed performance
Direction inferred from the company’s description.Scale
148
PeopleWording
Avoiding a definitive answer
How definitive the wording is.Items stated in the management plan
Partially revisedKey initiatives
01Solicitation of applications for voluntary retirement to optimize the workforce
02Withdrawal from GMP cell-processing contract services and prioritization of target modalities
03Discontinuation of the in-house clinical development project for gene therapy
04Clarification of management responsibility and streamlining of the management structure
Risks identified by the company
The transfer of the business is subject to the execution of a definitive agreement and the satisfaction of conditions stipulated in that agreement, among other matters, and has not been determined as of the present time.
Reason for revision or withdrawal
Implementation of structural reforms to improve profitability
| Item | Details |
|---|---|
| Plan name | Structural reforms to improve profitability |
| Progress against the plan | Partially revised |
| Key initiatives | Solicitation of applications for voluntary retirement to optimize the workforce, Withdrawal from GMP cell-processing contract services and prioritization of target modalities, Discontinuation of the in-house clinical development project for gene therapy, Clarification of management responsibility and streamlining of the management structure |
| Reason for revision or withdrawal | Implementation of structural reforms to improve profitability |
| Risks identified | The transfer of the business is subject to the execution of a definitive agreement and the satisfaction of conditions stipulated in that agreement, among other matters, and has not been determined as of the present time. |
| Publication date | 21 July 2026 |
Items this document does not state (19)
Plan periodSales TargetOperating profit targetOperating profit margin targetNet income targetROE targetROIC targetPayout ratio / DOE policyTreasury share acquisition policyCost of capitalSelf-assessment of PBR and share priceTotal investment planInvestment amount by sectorSegment targetNon-financial targetsPlan assumptionsResults under the previous planSize of the Target MarketDate of board resolution
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.As part of structural reforms to improve profitability, the company is implementing measures including workforce optimization, withdrawal from the GMP cell-processing contract manufacturing business and a focus on the targeted modalities, and streamlining of the management structure.
How to read this page
This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.